Vir Biotechnology (NASDAQ:VIR) and Kymera Therapeutics (NASDAQ:KYMR) Head-To-Head Contrast

Kymera Therapeutics (NASDAQ:KYMR) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Valuation & Earnings

This table compares Kymera Therapeutics and Vir Biotechnology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$78.59 million	34.63	-$146.96 million	($2.34)	-17.96
Vir Biotechnology	$62.04 million	16.43	-$615.06 million	($3.92)	-1.89

Kymera Therapeutics has higher revenue and earnings than Vir Biotechnology. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and Vir Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-191.26%	-24.96%	-20.27%
Vir Biotechnology	-678.40%	-36.71%	-31.00%

Insider & Institutional Ownership

65.3% of Vir Biotechnology shares are held by institutional investors. 15.8% of Kymera Therapeutics shares are held by insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Kymera Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kymera Therapeutics and Vir Biotechnology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0	4	13	1	2.83
Vir Biotechnology	0	2	3	0	2.60

Kymera Therapeutics presently has a consensus price target of $53.88, indicating a potential upside of 28.23%. Vir Biotechnology has a consensus price target of $36.40, indicating a potential upside of 391.89%. Given Vir Biotechnology’s higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Kymera Therapeutics.

Summary

Kymera Therapeutics beats Vir Biotechnology on 12 of the 15 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Vir Biotechnology

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.